SCHEMBL4280677

SCHEMBL4280677

CCOc1cc(C(N)=O)ccc1OC

nearest known ligand 0.90

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.90
▸ TSHR P16473 3/20 0.66
▸ PDE4A P27815 6/20 0.63
▸ PDE4B Q07343 6/20 0.63
▸ PDE4C Q08493 6/20 0.63
▸ PDE4D Q08499 6/20 0.63
▸ TP53 P04637 1/20 0.62
▸ NCOA1 Q15788 1/20 0.59
▸ NCOA3 Q9Y6Q9 1/20 0.59
▸ BPTF Q12830 1/20 0.59
▸ PARP10 Q53GL7 1/20 0.56
▸ HPGD P15428 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944861 0.95 MAPK1 (1.00) MAPK1TSHRPDE4APDE4BPDE4C
SCHEMBL1402177 0.93 MAPK1 (0.84) MAPK1TSHRPDE4APDE4BPDE4C
SCHEMBL28332599 0.88 MAPK1 (0.71) MAPK1TSHRPDE4APDE4BPDE4C
SCHEMBL4826029 0.88 TSHR (0.72) MAPK1TSHRPDE4APDE4BPDE4C
SCHEMBL5076592 0.86 TSHR (0.76) MAPK1TSHRPDE4APDE4BPDE4C
SCHEMBL3612256 0.86 TSHR (0.87) MAPK1TSHRPDE4APDE4BPDE4C
SCHEMBL1824358 0.86 MAPK1 (0.69) MAPK1TSHRPDE4APDE4BPDE4C
SCHEMBL15521570 0.85 MAPK1 (0.68) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL335681 0.85 MAPK1 (0.77) MAPK1TSHRPARP10L3MBTL1CYP1A2
SCHEMBL29415167 0.85 MAPK1 (0.77) MAPK1TSHRPARP10L3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 — — US disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 — — US disclosed
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-08-25 — — US disclosed
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-12 — — US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 — — US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 — — US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 — — US disclosed
WO-2016202806-A1 A NOVEL SYNTHETIC PATHWAY TOWARDS APREMILAST LEK PHARMACEUTICALS D.D. (SI) 2016-12-22 — — WO disclosed
WO-2016053855-A1 SPHINGOSINE-1-PHOSPATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-04-07 — — WO disclosed
EP-1954684-B1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2014-05-07 — — EP disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 — — US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 — — US disclosed
EP-1954684-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION Otsuka Pharmaceutical Co., Ltd. (JP) 2008-08-13 — — EP disclosed
WO-2007058338-A9 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2007-11-01 — — WO disclosed
WO-2007058338-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-05-24 — — WO disclosed
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 — — EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 — — US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 — — US disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 — — EP disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A MAPK1 453/4885TSHR 2109/4885PDE4A 2/4885
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPK1 233/4885TSHR 3320/4885PDE4A 5/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A MAPK1 453/4885TSHR 2109/4885PDE4A 2/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B MAPK1 1461/4885TSHR 1378/4885PDE4A 10/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A MAPK1 453/4885TSHR 2109/4885PDE4A 2/4885
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A MAPK1 453/4885TSHR 2109/4885PDE4A 2/4885
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A MAPK1 369/4885TSHR 1832/4885PDE4A 2/4885
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A MAPK1 453/4885TSHR 2109/4885PDE4A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback